TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06740630: A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Sponsor: GlaxoSmithKline · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 1840 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,772,230

Rescue Site Savings

+$2,498,490

Unlock Full NCT06740630 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06740630 Rescue Dossier →